Aims To compare the pharmacokinetic profile of intranasal alniditan during and outside migraine attacks, and to investigate the relationship between initial rise of alniditan plasma concentration, and headache improvement. Methods Twenty-seven migraine patients (age: 18-65 years) were randomized to receive alniditan 2 mg or 4 mg, and investigated both during and outside a migraine attack. Maximal plasma concentrations (C max ), time to C max (t max ), and the area under the curve over 2 h (AUC(0,2 h)), were calculated from the individual plasma concentration-time profile, obtained from 10 blood samples in each patient, during each of the two administrations. Results Alniditan was rapidly absorbed into the systemic circulation (t max =11min). All investigated pharmacokinetic parameters (C max , t max , AUC(0,2 h)) were similar during and outside migraine attacks, both in the 2 mg (n=13) and the 4 mg group (n=14). In the 4 mg group, during attacks, mean plasma alniditan concentration at 5 min after administration (C t=5 ) in responders (21±16 ng ml −1 ; n=10) was significantly higher than the C t=5 in nonresponders (3±3 ng ml −1 ; P=0.01; n=4). However, the C max and AUC(0,2 h) in responders (33±18 ng ml −1 and 12±6 ng ml −1 h) were also significantly higher than the C max and AUC(0,2 h) in nonresponders (13±9 ng ml −1 ; P=0.048 and 5±3 ng ml −1 h; P=0.03).Conclusions Absorption of alniditan nasal spray was not affected by migraine attacks, although 95% confidence intervals were wide. Early rise of plasma concentrations and the amount of drug in the circulation were related to headache improvement in the higher dose group.Keywords: 5-HT 1B/1D receptor agonist, alniditan, migraine, nasal spray, pharmacokinetics showed similar clinical efficacy to that of orally adminisIntroduction trated sumatriptan [9][10][11]. The absence of superiority of the nasal route could be caused by lack of nasal absorption During attacks most migraine patients suffer from gastrointestinal symptoms such as nausea, vomiting and either because most of the drug is swallowed or because of a possible influence of migraine attacks on the nasal diarrhoea [1]. In addition, gastric stasis delays and impairs the gastro-intestinal absorption of drugs [2], making oral mucosa resulting in decreased absorption. The magnitude of headache relief of 5-HT 1B/1D treatment of migraine sometimes unsatisfactory [3,4]. Subcutaneously administrated antimigraine drugs are an receptor agonists appears to be related to the initial rise of plasma levels of the drugs [8, 12, 13], rather than to alternative, but dislike of injections or an inability to selfadminister makes subcutaneous treatment unacceptable the total amount of drug in the circulation [14]. Rate of absorption (initial rise of plasma levels) can be measured to some patients. Absorption of drugs via the nasal mucosa circumvents the gastro-intestinal problems associby the concentration of drugs 5 min after administration. We hypothesized that patients without headache relief ated with migraine attacks an...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.